Browsing Tag
T-cell engager
4 posts
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.
How Purple Biotech’s CAPTN-3 platform achieved a tri-specific antibody manufacturing milestone with IM1240
Find out how Purple Biotech’s manufacturing milestone for IM1240 is validating the CAPTN-3 platform and transforming tri-specific antibody development.
FDA approves Janssen’s TECVAYLI for multiple myeloma treatment
The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced the US Food and Drug Administration’s approval…
AstraZeneca to acquire US biotech firm TeneoTwo for up to $1.27bn
UK-based pharma giant AstraZeneca has signed a deal worth up to $1.27 billion to acquire American biotech company…